{"id":797142,"date":"2026-03-19T19:36:02","date_gmt":"2026-03-19T19:36:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=797142"},"modified":"2026-03-19T19:36:02","modified_gmt":"2026-03-19T19:36:02","slug":"hepatic-tumor-clinical-trial-landscape-strengthens-as-75-companies-accelerate-innovation-in-emerging-therapies-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/hepatic-tumor-clinical-trial-landscape-strengthens-as-75-companies-accelerate-innovation-in-emerging-therapies-delveinsight_797142.html","title":{"rendered":"Hepatic Tumor Clinical Trial Landscape Strengthens as 75+ Companies Accelerate Innovation in Emerging Therapies | DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/upload\/2026\/03\/1773859777.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Hepatic Tumor Clinical Trial Landscape Strengthens as 75+ Companies Accelerate Innovation in Emerging Therapies | DelveInsight\" src=\"https:\/\/www.abnewswire.com\/upload\/2026\/03\/1773859777.jpg\" alt=\"Hepatic Tumor Clinical Trial Landscape Strengthens as 75+ Companies Accelerate Innovation in Emerging Therapies | DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Hepatic Tumor Pipeline<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">Hepatic Tumor companies include Can Fite Biopharma, MiNA Therapeutics, Medivir AB, Janssen Research &#038; Development, LLC, Etnova Therapeutics Corp., SillaJen Biotherapeutics, Akeso Biopharma, Shanghai Junshi Biosciences, Genmab\/Janssen Biotech, Bio-Thera Solutions, Ocuphire Pharma, Surface Oncology, Genoscience, Onyx Pharmaceuticals, Qurient Co., Ltd., Kowa Company, Ltd., and Eureka Therapeutics Inc, among others.<\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s latest report, <strong>&ldquo;Hepatic Tumor Pipeline Insight 2026,&rdquo;<\/strong> delivers an extensive evaluation of the evolving therapeutic landscape, highlighting the contributions of more than 75 companies actively developing over 75 pipeline candidates for hepatic tumors. The report offers a deep dive into both clinical and preclinical drug candidates, along with a comprehensive assessment based on product type, development stage, route of administration, and molecular classification. It also sheds light on discontinued and inactive programs within this domain.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Explore the latest advancements and emerging treatment options in the Hepatic Tumor pipeline: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hepatic-tumor-pipeline-insight\">https:\/\/www.delveinsight.com\/sample-request\/hepatic-tumor-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key Highlights from the Hepatic Tumor Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>On <strong>February 20, 2026<\/strong>, Crinetics Pharmaceuticals Inc. announced a Phase III clinical trial assessing the efficacy and safety of paltusotine in adult patients with carcinoid syndrome. The study design includes an 11-week screening period, a 16-week randomized double-blind phase, a 104-week open-label extension, and a 4-week follow-up phase.<\/li>\n<li>On <strong>February 09, 2026<\/strong>, Stanford University initiated a Phase II trial evaluating real-time MRI-guided adaptive stereotactic ablative radiotherapy for liver cancers, utilizing a single-session, simulation-free approach.<\/li>\n<li>DelveInsight&rsquo;s findings highlight a dynamic and competitive pipeline landscape, with over 75 organizations advancing more than 75 therapeutic candidates aimed at treating hepatic tumors.<\/li>\n<li>Prominent players in this space include Can Fite Biopharma, MiNA Therapeutics, Medivir AB, Janssen Research &amp; Development, LLC, Etnova Therapeutics Corp., SillaJen Biotherapeutics, Akeso Biopharma, Shanghai Junshi Biosciences, Genmab\/Janssen Biotech, Bio-Thera Solutions, Ocuphire Pharma, Surface Oncology, Genoscience, Onyx Pharmaceuticals, Qurient Co., Ltd., Kowa Company, Ltd., and Eureka Therapeutics Inc, among others.<\/li>\n<li>Key investigational therapies gaining attention include Atezolizumab, Bevacizumab (15 mg\/kg), Tiragolumab, NIK-333 (peretinoin), Sorafenib, SonoVue&reg;, Talaporfin sodium, NV1020, and Pemetrexed.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Gain detailed insights into clinical trials, pipeline drugs, and leading innovators: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hepatic-tumor-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Hepatic Tumor Treatment Drugs<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Emerging Drug Profiles in Hepatic Tumor Treatment<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Namodenoson &ndash; Can Fite Biopharma<\/strong><\/p>\n<p style=\"text-align: justify;\">Namodenoson is an orally administered small molecule targeting the A3 adenosine receptor (A3AR). It is being developed for multiple oncology indications, including hepatocellular carcinoma, pancreatic cancer, and metabolic-associated steatohepatitis (MASH). Currently in Phase III trials, it represents a promising late-stage candidate for liver cancer treatment.<\/p>\n<p style=\"text-align: justify;\"><strong>MTL-CEBPA &ndash; MiNA Therapeutics<\/strong><\/p>\n<p style=\"text-align: justify;\">MTL-CEBPA is an innovative RNA-based therapy designed to restore normal levels of the C\/EBP-&alpha; protein, thereby reducing immune suppression in myeloid cells. Developed as part of combination cancer therapies, it is currently being evaluated in Phase II clinical studies.<\/p>\n<p style=\"text-align: justify;\"><strong>Amivantamab &ndash; Janssen Research &amp; Development, LLC<\/strong><\/p>\n<p style=\"text-align: justify;\">Amivantamab is a fully human bispecific antibody targeting EGFR and MET mutations. It works through immune cell-directed activity and antibody-dependent cytotoxicity mechanisms. The therapy is currently in Phase II trials for hepatic tumors.<\/p>\n<p style=\"text-align: justify;\"><strong>Fostroxacitabine bralpamide &ndash; Medivir AB<\/strong><\/p>\n<p style=\"text-align: justify;\">This next-generation chemotherapy agent selectively delivers cytotoxic compounds to tumor cells while sparing healthy tissue. Acting as a nucleotide DNA polymerase inhibitor, it is being studied in Phase I\/II trials and is administered orally.<\/p>\n<p style=\"text-align: justify;\"><strong>ETN101 &ndash; Etnova Therapeutics Corp.<\/strong><\/p>\n<p style=\"text-align: justify;\">ETN101 is a multi-target tyrosine kinase inhibitor designed to treat hepatocellular carcinoma. It blocks key signaling pathways such as PI3K\/AKT and RAS-MAPK and targets FLT3, KIT, VEGFR2, and PDGFRB. Currently in Phase I trials, it shows potential as both a first-line and follow-up therapy.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Comprehensive Insights Offered by the Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>In-depth profiles of companies actively engaged in hepatic tumor drug development, along with their respective therapeutic portfolios<\/li>\n<li>Segmentation of pipeline candidates into early-, mid-, and late-stage development categories<\/li>\n<li>Overview of both active and inactive programs within the hepatic tumor pipeline<\/li>\n<li>Evaluation of drugs based on mechanism of action, route of administration, molecular type, and therapeutic approach (monotherapy vs. combination therapy)<\/li>\n<li>Detailed analysis of strategic collaborations, licensing agreements, and funding activities shaping future market growth<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Explore the next generation of therapies and clinical advancements: <a rel=\"nofollow\" href=\"file:\/\/\/E:\/Ankit%20Laptop%20Data%20C%20Drive\/Desktop\/ABNewswire\/Press%20Releases\/:%20https:\/www.delveinsight.com\/sample-request\/hepatic-tumor-pipeline-insight\">New Hepatic Tumor Drugs<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key Companies in the Hepatic Tumor Space<\/strong><\/p>\n<p style=\"text-align: justify;\">The competitive landscape features a diverse mix of biotechnology firms and pharmaceutical companies, including Can Fite Biopharma, MiNA Therapeutics, Medivir AB, Janssen Research &amp; Development, LLC, Etnova Therapeutics Corp., SillaJen Biotherapeutics, Akeso Biopharma, Shanghai Junshi Biosciences, Genmab\/Janssen Biotech, Bio-Thera Solutions, Ocuphire Pharma, Surface Oncology, Genoscience, Onyx Pharmaceuticals, Qurient Co., Ltd., Kowa Company, Ltd., and Eureka Therapeutics Inc, among others.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Therapeutic Segmentation<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>By Route of Administration:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Oral<\/li>\n<li>Parenteral<\/li>\n<li>Intravenous<\/li>\n<li>Subcutaneous<\/li>\n<li>Topical<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>By Molecule Type:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Monoclonal antibodies<\/li>\n<li>Peptides<\/li>\n<li>Polymers<\/li>\n<li>Small molecules<\/li>\n<li>Gene therapies<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Gain expert insights on market drivers, barriers, and future outlook: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hepatic-tumor-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Hepatic Tumor Market Drivers and Barriers<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Geographical Coverage:<\/strong> Global<\/li>\n<li><strong>Pipeline Therapies Covered:<\/strong> Atezolizumab, Bevacizumab, Tiragolumab, NIK-333, Sorafenib, SonoVue&reg;, Talaporfin sodium, NV1020, Pemetrexed, and others<\/li>\n<li><strong>Therapeutic Assessment:<\/strong> Monotherapy, combination therapy, and hybrid approaches<\/li>\n<li><strong>Development Stages Covered:<\/strong> Discovery, preclinical, Phase I, Phase II, and Phase III<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download the complete report to uncover key opportunities and unmet needs in the hepatic tumor market: Hepatic Tumor Companies, Key Products and Unmet Needs &#8211; <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hepatic-tumor-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/hepatic-tumor-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Introduction<\/li>\n<li>Executive Summary<\/li>\n<li>Disease Overview<\/li>\n<li>Pipeline Therapeutics<\/li>\n<li>Therapeutic Assessment<\/li>\n<li>Late-, Mid-, and Early-Stage Products<\/li>\n<li>Comparative Analyses<\/li>\n<li>Key Companies and Products<\/li>\n<li>Unmet Needs<\/li>\n<li>Market Drivers and Barriers<\/li>\n<li>Future Outlook and Analyst Perspectives<\/li>\n<li>Appendix<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a globally recognized market research and consulting firm specializing in the healthcare and life sciences sectors. The company provides actionable insights and data-driven analysis to support strategic decision-making. With a team of seasoned experts, DelveInsight delivers customized solutions that help clients stay competitive and capitalize on emerging market opportunities.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=hepatic-tumor-clinical-trial-landscape-strengthens-as-75-companies-accelerate-innovation-in-emerging-therapies-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +14699457679<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=hepatic-tumor-clinical-trial-landscape-strengthens-as-75-companies-accelerate-innovation-in-emerging-therapies-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Hepatic Tumor Pipeline Hepatic Tumor companies include Can Fite Biopharma, MiNA Therapeutics, Medivir AB, Janssen Research &#038; Development, LLC, Etnova Therapeutics Corp., SillaJen Biotherapeutics, Akeso Biopharma, Shanghai Junshi Biosciences, Genmab\/Janssen Biotech, Bio-Thera Solutions, Ocuphire Pharma, Surface Oncology, Genoscience, Onyx Pharmaceuticals, &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/hepatic-tumor-clinical-trial-landscape-strengthens-as-75-companies-accelerate-innovation-in-emerging-therapies-delveinsight_797142.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-797142","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/797142","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=797142"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/797142\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=797142"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=797142"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=797142"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}